Literature DB >> 17409271

Possible bioactivation pathways of lamotrigine.

Wei Lu1, Jack P Uetrecht.   

Abstract

The anticonvulsant lamotrigine is associated with idiosyncratic drug reactions, especially skin rashes. Most idiosyncratic reactions are believed to be caused by reactive metabolites. Previous studies have found evidence that an arene oxide is formed in rats; however, when we incubated radiolabeled lamotrigine with rat liver microsomes virtually no covalent binding was detected, and the expected downstream phenolic metabolites are not observed in humans. Rare cases of agranulocytosis have been associated with lamotrigine therapy, and we found that lamotrigine is oxidized to two different N-chloro products by HOCl. The more reactive N-chloro metabolite forms an adduct with N-acetylhistidine, and covalent binding was observed when radiolabeled lamotrigine was incubated with myeloperoxidase/H(2)O(2)/Cl(-). Another lamotrigine metabolite is an N-oxide. If this N-oxide were sulfated, it might be sufficiently reactive to bind to protein. The synthetic N-sulfate reacted with N-acetylserine; however, no covalent binding was detected when the radiolabeled N-oxide was incubated with sulfotransferase. We also investigated the possibility that lamotrigine might be oxidized to a free radical by other peroxidases or oxidized by other enzymes such as prostaglandin H synthase or tyrosinase, but no evidence of oxidation was found, and lamotrigine did not cause any detectable increase in lipid peroxidation in vivo. In view of the virtual lack of covalent binding to hepatic microsomes and the lack of any other likely pathway leading to metabolic activation in the skin, it is possible that the parent drug rather than a reactive metabolite causes lamotrigine-induced skin rashes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17409271     DOI: 10.1124/dmd.107.015271

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  5 in total

Review 1.  Role of biotransformation studies in minimizing metabolism-related liabilities in drug discovery.

Authors:  Yue-Zhong Shu; Benjamin M Johnson; Tian J Yang
Journal:  AAPS J       Date:  2008-03-13       Impact factor: 4.009

2.  Adverse Cutaneous Drug Reactions Associated with Old- and New- Generation Antiepileptic Drugs Using the Japanese Pharmacovigilance Database.

Authors:  Keiko Hosohata; Ayaka Inada; Saki Oyama; Iku Niinomi; Tomohito Wakabayashi; Kazunori Iwanaga
Journal:  Clin Drug Investig       Date:  2019-04       Impact factor: 2.859

3.  Three cases of reversible agranulocytosis after treatment with lamotrigine.

Authors:  Yong Min Ahn; Kunjong Kim; Yong Sik Kim
Journal:  Psychiatry Investig       Date:  2008-06-30       Impact factor: 2.505

4.  Antioxidants as a preventive treatment for epileptic process: a review of the current status.

Authors:  Boštjan Martinc; Iztok Grabnar; Tomaž Vovk
Journal:  Curr Neuropharmacol       Date:  2014-12       Impact factor: 7.363

5.  Lamotrigine-Valproic Acid Interaction Leading to Stevens-Johnson Syndrome.

Authors:  Marta Vázquez; Cecilia Maldonado; Natalia Guevara; Andrea Rey; Pietro Fagiolino; Antonella Carozzi; Carlos Azambuja
Journal:  Case Rep Med       Date:  2018-08-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.